+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020

  • ID: 5146864
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 180 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 3SBio Inc
  • BioXpress Therapeutics SA
  • GC Pharma
  • Hutchison MediPharma Ltd
  • Novartis AG
  • Principia Biopharma Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide also reviews the key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 11, 10, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3SBio Inc
  • BioXpress Therapeutics SA
  • GC Pharma
  • Hutchison MediPharma Ltd
  • Novartis AG
  • Principia Biopharma Inc
Introduction
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H2 2020
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H2 2020
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Argenx SE, H2 2020
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2020
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • 3SBio Inc
  • Amgen Inc
  • Argenx SE
  • Beijing Tide Pharmaceutical Co Ltd
  • Biotest AG
  • BioXpress Therapeutics SA
  • Chengdu Rongsheng Pharmaceutical Co Ltd
  • Clover Biopharmaceuticals
  • CSL Ltd
  • Enzene Biosciences Ltd
  • GC Pharma
  • Genosco Inc
  • Genzyme Corp
  • HanAll Biopharma Co Ltd
  • Hutchison MediPharma Ltd
  • Iltoo Pharma
  • Jiangsu Hengrui Medicine Co Ltd
  • Kezar Life Sciences Inc
  • KM Biologics Co Ltd
  • Momenta Pharmaceuticals Inc
  • Novartis AG
  • Pfizer Inc
  • Pharmagenesis Inc
  • Pharmapraxis
  • Principia Biopharma Inc
  • Protalex Inc
  • Qilu Pharmaceutical Co Ltd
  • Rigel Pharmaceuticals Inc
  • Shandong Quangang Pharmaceutical Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • UCB SA
Note: Product cover images may vary from those shown
Adroll
adroll